Island Pharmaceuticals LtdASX: ILA

USAMRIID Marburg study advances towards dosing

· Issued by Island Pharmaceuticals Ltd via ASX

Filed with ASX · · 3 pages · English

Release

Island Pharmaceuticals Limited ACN 641 183 842 | Registered office: Suite 1.01, 117 Camberwell Rd, Hawthorn East VIC 3123, Australia 19 October 2026 ASX Announcement USAMRIID Marburg NHP study advances as 22 non-human primates successfully complete screening • Screening and preparation...

Island Pharmaceuticals Ltd on 6ix

Story so far

Earlier from Island Pharmaceuticals

All Island Pharmaceuticals news releases